Acer Therapeutics Inc.

Pfizer Corporation

Bend Research, Inc.

Bellerophon Bcm LLC

Ben Research, Inc.

Joshua R Shockey

Leah Elizabeth Appel

Dwayne Thomas Friesen

D Christopher Schelling

Roderick Jack Ray

Marshall David Crew

Sanjay Konagurthu

Edward Dennis LaChapelle

James William West

David D Newbold

David Keith Lyon

Scott B McCray

Jennifer Hsing-Chung Chu

Leah E Appel

The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative disorders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.

Palatable compositions including sodium phenylbutyrate and uses thereof

The present invention provides methods for the treatment of urea cycle disorders and Maple Syrup Urine Disease.

Methods of treating urea cycle disorders and maple syrup urine disease

A pharmaceutical composition comprises multiparticulates comprising a melt-congeal core and a solid amorphous dispersion layer of a poorly water soluble drug and polymer. The multiparticulates are suitable for improving bioavailability of poorly water soluble drugs. The melt-congeal cores facilitate application of the solid amorphous dispersion layer, and allow incorporation of additional optional components to the core so as to adjust the release of drug from the multiparticulate.

Multiparticulates of spray-coated drug and polymer on a meltable core

Described is a microfluidic process for manufacturing partially cross-linked alginate solution, wherein the alginate solution is a homogenous liquid which exhibits an elastic response (G') which is equal to or greater than its viscous response (G&#x2033;). In particular, the process may comprise microfluidic mixing of sodium alginate and calcium gluconate solutions to provide an injectable partially cross-linked alginate solution.

Process for manufacturing partially cross-linked alginate solution

A process is described for producing drug-containing multiparticulates with improved stability, characterized by an improvement in one or more of chemical stability, physical stability, or dissolution stability.

Multiparticulate compositions with improved stability

Reduced levels of drug degradation in drug-containing multiparticulates are obtained by an extrusion/melt-congeal process.

Extrusion process for forming chemically stable drug multiparticulates

Growing community of inventors

Bend, OR, United States of America

Joshua R Shockey